Reach Separations links up with Evotec in purification deal

Published: 19-Mar-2014

Nottingham company will provide expertise in small molecule chromatography

Reach Separations has concluded an alliance with German drug discovery company Evotec, which will see the UK-based company provide additional purification and analytical capability to support Evotec’s pharmaceutical and biotech clients worldwide.

As part of the agreement, the BioCity Nottingham-based purification specialist will become a technology partner to Evotec and provide expertise in small molecule chromatography.

The two companies have been working together since 2012, which has provided a solid foundation for this agreement.

Under the agreement, Evotec says it will be able to improve the turnaround of chiral analysis and purification on projects, without needing to make significant investment in additional equipment and facilities.

Reach Separations is capable of purifying from mg scale to in excess of 250g. It will now look after all chiral purification above 0.3g and 50% of all chiral analysis and purification under 0.3g for Evotec.

Peter Ridgway, Business Development Director at Reach Separations, said: 'We are delighted to have struck a collaboration with one of the world’s leading drug discovery research organisations.

'To support the increasing workload this new partnership brings, we have invested in expanded laboratory space, taken on more scientists and increased our instrumentation capability.'

Dr David Hallett, EVP of Discovery Chemistry at Evotec, said the team at Reach Separations has considerable expertise in the fields of chiral, reverse phase and normal phase chromatography.

'By adding Reach Separations to our exclusive portfolio of technology partners, it will allow us to streamline our processes that will allow us to meet clients’ project milestones even quicker.'

You may also like